CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth

PM Reeves, MA Abbaslou, FRW Kools… - Anti-cancer …, 2017 - journals.lww.com
The standard of care for ovarian cancer includes initial treatment with chemotherapy.
Despite initial efficacy, over 70% of patients develop recurrence; thus, there is a need to
identify novel approaches that can improve therapeutic outcomes. We evaluated AMD3100
(Plerixafor), an FDA-approved CXCR4 inhibitor, as a potential adjunctive therapy for low-
dose Taxol (Paclitaxel) by assessing the impact on in-vitro ovarian cancer cell proliferation.
Proliferation was a measure for both human TOV-112D and murine ID8 ovarian cancer cells …
以上显示的是最相近的搜索结果。 查看全部搜索结果